Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Raw Materials (2023 - 2024)

Tarsus Pharmaceuticals (TARS) has 2 years of Raw Materials data on record, last reported at $2.5 million in Q1 2024.

  • For Q1 2024, Raw Materials changed N/A year-over-year to $2.5 million; the TTM value through Mar 2024 reached $2.5 million, changed N/A, while the annual FY2023 figure was $2.5 million, N/A changed from the prior year.
  • Raw Materials reached $2.5 million in Q1 2024 per TARS's latest filing, roughly flat from $2.5 million in the prior quarter.
  • Across five years, Raw Materials topped out at $2.5 million in Q4 2023 and bottomed at $2.5 million in Q4 2023.